[1]
|
Mak, S. and Newton, G.E. (2001) The Oxidative Stress Hypothesis of Congestive Heart Failure. Chest, 120, 2035-2046.
|
[2]
|
Reunanen, A., Knekt, P. and Aaran, P.K. (1992) Serum Ceruloplasmin Level and the Risk of Myocardial Infarction and Stroke. American Journal of Epidemiology, 136, 1082-1090.
|
[3]
|
Mänttäri, M., Manninen, V., Huttunen, V.K., et al. (1994) Serum Ferritin and Ceruloplasmin as Coronary Risk Factors European Heart Journal, 15, 1599-1603.
|
[4]
|
Klipstein-Grobusch, K., Grobbee, D.E., Koster, F.E., et al. (1999) Serum Ceruloplasmin as a Coronary Risk Factor in the Elderly. The Rotterdam Study British Journal of Nutrition, 81, 139-144.
|
[5]
|
Ridker, P.M., Cushman, M., Stampfer, M.J., et al. (1997) Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men. New England Journal of Medicine, 336, 973-979. http://dx.doi.org/10.1056/NEJM199704033361401
|
[6]
|
Dadu, R.T., Dodge, R., Nambi, V., et al. (2013) Ceruloplasmin and Heart Failure in the Atherosclerosis Risk in Communities Study. Circ Heart Fail, 6, 936-943. http://dx.doi.org/10.1161/CIRCHEARTFAILURE.113.000270
|
[7]
|
Hammadah, M., Fan, Y., Wu, Y., et al. (2014) Prognostic Value of Elevated Serum Ceruloplasmin Levels in Patients with Heart Failure. Journal of Cardiac Failure, 20, 946-952.
|
[8]
|
Mueller, T., Dieplinger, B., Gegenhuber, A., et al. (2008) Increased Plasma Concentrations of Soluble ST2 Are Predictive for 1-Year Mortality in Patients with Acute Destabilized Heart Failure. Clinical Chemistry, 54, 752-756. http://dx.doi.org/10.1373/clinchem.2007.096560
|
[9]
|
Manzano-Fernández, S., Mueller, T., Pascual-Figal, D., et al. (2011) Usefulness of Soluble Concentrations of Interleukin family member ST2 as Predictor of Mortality in Patients with Acutely Decompensated Heart Failure Relative to Left Ventricular Ejection Fraction. The American Journal of Cardiology, 107, 259-267. http://dx.doi.org/10.1016/j.amjcard.2010.09.011
|
[10]
|
de Boer, R.A., Voors, A.A., Muntendam, P., et al. (2009) Galectin-3: A Novel Mediator of Heart Failure Development and Progression. European Journal of Heart Failure, 11, 811-817.
|
[11]
|
Shiva, S., Wang, X., Ringwood, L.A., et al. (2006) Ceruloplasmin Is a No Oxidase and Nitrite Synthase That Determines Endocrine No Homeostasis. Nature Chemical Biology, 2, 486-493. http://dx.doi.org/10.1038/nchembio813
|
[12]
|
Shukla, N., Maher, J., Masters, J., et al. (2006) Does Oxidative Stress Change Ceruloplasmin from a Protective to a Vasculopathic Factor? Atherosclerosis, 187, 238-250. http://dx.doi.org/10.1016/j.atherosclerosis.2005.11.035
|
[13]
|
Tang, W.H., Wu, Y., Hartiala, J., Hazen, S.L., et al. (2012) Clinical and Genetic Association of Serum Ceruloplasmin with Cardiovascular Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 32, 516-522. http://dx.doi.org/10.1161/ATVBAHA.111.237040
|
[14]
|
Engstrom, G., Hedblad, B., Tyden, P. and Lindgarde, F. (2009) Inflammation-Sensitive Plasma Proteins Are Associated with Increased Incidence of Heart Failure: A Population-Based Cohort Study. Atherosclerosis, 202, 617-622. http://dx.doi.org/10.1016/j.atherosclerosis.2008.05.038
|
[15]
|
Xu, Y., Lin, H., Zhou, Y., et al. (2013) Ceruloplasmin and the Extent of Heart Failure in Ischemic and Nonischemic Cardiomyopathy Patients. Mediators of Inflammation, 2013, Article ID: 348145. http://dx.doi.org/10.1155/2013/348145
|
[16]
|
Hendrichová, M., Málek, F., Koprivová, H., et al. (2010) Correlation of NT-proBNP with Metabolic Liver Function as Assessed with 13C-Methacetin Breath Test in Patients with Acute Decompensated Heart Failure. International Journal of Cardiology, 144, 321-322. http://dx.doi.org/10.1016/j.ijcard.2009.03.022
|
[17]
|
Sharma, U.C., Pokharel, S., van Brakel, T.J., et al. (2004) Galectin-3 Marks Activated Macrophages in Failure-Pronehy Pertrophied Hearts and Contributes to Cardiac Dysfunction. Circulation, 110, 3121-3128. http://dx.doi.org/10.1161/01.CIR.0000147181.65298.4D
|